Category Archives: Genetic Therapy

Amber Freeds singular mission is to help scientists develop a treatment for her son. But the pandemic has put the success of that mission into question.

Freed is a mother to twins Riley and Maxwell, who just turned 3 this year. Riley is a healthy toddler. But Maxwell has a rare genetic disease that has led to delays in his development. Hes nonverbal, and he has a movement disorder. The condition responsible for these symptoms is called SLC6A1, after the gene thats affected, and Maxwell was only the 34th person in the world to get this diagnosis. if left untreated, the disease could soon cause debilitating epilepsy.

When doctors broke the news of the diagnosis to Freed, they told her there was no treatment or cure for her son, and that her family would have to prepare to live with Maxwells condition. But Amber didnt accept that.

Every instinct in my body said, Youll have your whole lifetime to cry for yourself, Freed said. At this exact moment, you put your feelings and sadness aside. This isnt about you. This is about Maxwell. And you fight like the third monkey on the loading deck to Noahs Ark, and its starting to rain.

This is how Freeds quest began. She taught herself microbiology, so she could understand her sons condition. She lobbied scientists to take up the research, which wasnt on their radar given how rare the disease is. She convinced scientists in China to make genetically engineered mice that could be sent to the US and act as a model of Maxwells disease. And she fundraised a necessary step given the high cost of the gene therapy research.

All told, shes raised more than $1 million. What were doing will be the building blocks of all gene therapies to come after us, Freed told Arielle Duhaime-Ross on an episode of Reset in January.

Even though she was racing against time, she was optimistic that Maxwell would be treated this year, as experiments on the genetically modified mice were about to begin.

Then the pandemic hit.

Covid-19 has brought most non-coronavirus medical research to a halt, and closed labs.

I never anticipated or thought something like this could happen, Freed said, but also it was a state of devastation like I felt when Maxwell was originally diagnosed that lightning hit us. The unthinkable happened. And here, lightning has hit again. A black swan event for the world that no one could have anticipated.

Freed came back to Reset to talk about the impact of the pandemic on Maxwell and her family as well as rare disease research as a whole. Listen to the full episode below.

The episode also features a conversation with BuzzFeed science reporter Dan Vergano, who first wrote about Ambers story and who talks about how the closure has impacted thousands of other kids with rare diseases, as well as clinical trials for other types of medical research.

Listen and read more:

Listen to the original Reset story from January

Dan Verganos reporting on this story for BuzzFeed

Back in January, Dans piece on how the mice were being used to develop a treatment

Milestones for Maxwell, Amber Freeds website

Continue reading here:
A treatment for this toddlers rare genetic condition was in sight. Then the pandemic hit. - Vox.com

ALLENDALE, NJ., USA and MUNICH, Germany, May 11, 2020 / B3C newswire / -- Hitachi Chemical Advanced Therapeutics Solutions, LLC (HCATS) and apceth Biopharma GmbH (apceth), both subsidiaries of Hitachi Chemical Co., Ltd. (Hitachi Chemical) today announced that they have expanded their relationship with bluebird bio (NASDAQ: BLUE) with long-term development and manufacturing services agreements for clinical and commercial supply for multiple therapies, including:

These agreements are the latest in a long-standing partnership between bluebird bio and Hitachi Chemical. In 2011, HCATS, which represents the North America region of Hitachi Chemicals global regenerative medicine business, and bluebird bio entered into their first clinical services agreement. A commercial drug product manufacturing service agreement was also established between bluebird bio and apceth (which represents the Europe region of Hitachi Chemicals global regenerative medicine business) in 2016. In January 2020, apceth announced its readiness to begin commercial manufacturing of ZYNTEGLO with bluebirds announcement of the launch in Germany.

"With three products in our severe genetic disease franchise to potentially launch between now and 2022, securing long-term commercial drug product manufacturing capacity is critical to our ability to deliver for patients, " said Nick Leschly, chief bluebird. "Our partnership with Hitachi Chemical is a significant example of our continued progress on this front and we believe Hitachi Chemicals recent expansion will help support our growing commercial needs. We are pleased to benefit from their expertise as well as their footprint in both the US and Europe as we work to bring transformative therapies to patients in need."

We are excited to partner with bluebird bio through our new U.S. facility, utilizing our state-of-the-art capabilities and systems for late-stage clinical testing and ultimately commercial production once all applicable regulatory approvals are granted, said Robert Preti, Ph.D., Chief Strategy Officer, Hitachi Chemical Life Science Business Headquarters. It is our honor to support bluebird bio in the manufacture of their potentially transformative gene therapies, to the benefit of patients in both the United States and Europe, as the foundation for our collaboration to address this devastating disease

We are very happy to deepen our trustful and productive strategic partnership with bluebird bio, commented Dr. Christine Guenther, Deputy General Manager of the Hitachi Chemical Regenerative Medicine Business Sector and CEO of apceth Biopharma GmbH. The apceth team is proud to be part of bluebird bios most exciting pioneering work for the advancement of cell and gene therapies and to supply patients suffering from severe genetic illnesses with potentially life-changing treatments.

This medicinal product is subject to additional monitoring.

About Hitachi Chemicals Regenerative Medicine BusinessHitachi Chemical provides cell and gene therapy contract development and manufacturing organization (CDMO) services at current Good Manufacturing Practices (cGMP) standards, including clinical manufacturing, commercial manufacturing, and manufacturing development. The global footprint of the business is over 200,000 square feet and includes operations in North America (Allendale, New Jersey and Mountain View, California), Europe (Munich, Germany), and Japan (Yokohama). The business leverages two decades of experience exclusively focused on the cell therapy industry.

For more information on North America services, please visit http://www.pctcelltherapy.comFor more information on Europe services, please visit http://www.apceth.comFor more information on Japan services, please visit http://www.hitachi-chem.co.jp/english

Contacts

Hitachi Chemical Advanced Therapeutics SolutionsEric PowersDirector, Marketing and CommunicationsThis email address is being protected from spambots. You need JavaScript enabled to view it.

apceth Biopharma GmbHAlmut WindhagerManager, Business Development and CommunicationsThis email address is being protected from spambots. You need JavaScript enabled to view it.

Keywords: Humans; Regenerative Medicine; Thalassemia; HLA Antigens; Hematopoietic Stem Cell Transplantation; Anemia, Sickle Cell; Hematopoietic Stem Cells; Genetic Therapy

Published by B3C newswire and shared through Newronic

See more here:
Hitachi Chemical Advanced Therapeutics Solutions and apceth Biopharma GmbH Enter into Strategic Clinical and Commercial Manufacturing Agreements with...

Chicago hedge fund firm Citadel is known for buying and selling stocks, bonds and derivatives across public markets. But lately it's been pumping millions of dollars into private biotech companies.

The firm's Surveyor Capital fund has invested about $150 million in 17 such companies, mainly in the biopharmaceutical field, since February 2018.

That venture investing is a small portion of billionaire Ken Griffin's $30 billion Citadel business, but it's part of a striking and expanding departure from his 30-year focus on public markets. Placing capital with young biotech companies can be risky, but Surveyor has captured big gains in initial public offerings. Those types of returns have increasingly attracted investors to the biotech sector over the past decade, and that wave of interest is likely to keep climbing with the new hunt for coronavirus treatments.

"We're really at a significant growth phase in biotech in terms of new treatments hitting the market," says Sean Nolan, the former CEO of Chicago-based AveXis, a gene therapy company that combats a rare genetic disease in children. "The need created by the COVID virus is going to spur opportunities in biotech to develop treatments and vaccines."

While Surveyor isn't in coronavirus-specific startups, Seattle research firm Pitchbook has detailed the breadth and depth of Citadel's investing in the area, echoing press statements from fledgling biotech companies that have received the money. Citadel spokeswoman Megan Ingersoll declines to comment.

Surveyor, with 175 investment professionals, is one of a handful of Citadel funds investing worldwide, pursuing equity strategies to deliver returns for Griffin, clients and firm employees. So far this year, Citadel's flagship Wellington fund has achieved a 10% gain through April, according to a person familiar with the results, despite the market rout.

Surveyor bought AveXis shares at $20 apiece in a February 2016 initial public offering and shared in its windfall less than two years later when industry giant Novartis bought AveXis for $8.7 billion, or $218 a share, in April 2018. "Surveyor, at least in the AveXis instance, had a long view and was a very good investor along the way," Nolan says.

Now a different Surveyor team is getting into biotech companies pre-IPO, even earlier in the attempt to move a research idea through clinical trials to federal regulatory approvals to production. There are bigger gains to be had from investing at lower valuations before companies go public, but there are also more chances to stumble. "The venture capitalists are there earlier because they're willing to take more risk," Nolan says.

Surveyor always invests as part of a group that doesn't disclose how much each investor contributes, but based on the group amounts and dynamics, Surveyor is likely in for about $5 million to $15 million per company.

So far this year, Surveyor joined with other investors to place $170 million with Cambridge, Mass., gene and cell therapy accelerator ElevateBio; $105 million with Boston-based hearing loss therapy company Akouos; $100 million with South San Francisco-based Pliant Therapeutics, which is developing treatments to fight fibrotic diseases; and $88 million with San Francisco-based Spruce Biosciences, targeting treatments to battle endocrine disorders.

At that rate, Surveyor is on track to exceed the eight investments it made last year and the five in 2018. The dollar amounts of Surveyor's group investments have also mainly climbed, perhaps reflecting the arena's rising allure.

The IPO typically gives a 30% boost to investments, says Keith Crandell, whose Chicago-based investment firm, Arch Venture Partners, has carved out a niche in biotech venture investing. "Generally, you see the values pop, so there's talk about arbitraging that private-public step-up," says Crandell, an Arch managing director.

More investment funds are crossing over from public to private markets to grab that upside, he says. The closer companies get to approval for starting trials on humans, the more capital they require and the bigger sums they attract. "If you have a success in the clinic, it's worth a lot of money," he says, but "none of these are certain things."

Still, it takes only a couple of big wins to make a pack of investments successful. Surveyor's $85 million group investment in New York-based cancer treatment company Zentalis Pharmaceuticals in December delivered big returns last month when the company went public. Its shares, priced at $18 in the IPO, jumped as much as 50% on their first day of trading before closing at $23.20 and have since climbed to $31.93.

Surveyor's pre-IPO investment in Beltsville, Md.-based NextCure in November 2018 also panned out. In the May 2019 first-time stock sale, shares priced at $15 apiece and have more than doubled a year later, closing at $35.89 on May 7.

Crandell observes that a significant portion of Surveyor's investments are in gene and cell therapy and in cancer-fighting treatments. Those therapies have "performed well," particularly in oncology, "because the science has proved out," he says.

Surveyor may be increasing its odds by backing startups that have already landed "top-tier" venture capitalists in earlier stages of fundraising, he says, noting prominent firms like Third Rock Ventures and Canaan Partners. Surveyor's group co-investors aren't slouches, either, including Fidelity Management & Research and Franklin Templeton Investments.

Nonetheless, some of Surveyor's picks have declined. It invested in Sutro Biopharma in July 2018 before the company's September 2018 IPO, which priced at $15 a share. The shares have since sunk by more than a third to $9.62 on May 7.

All in all, Surveyor is still doing what Citadel does best, hedging its bets, but with more investor interest in biotech, the biggest gains may be harder to come by.

This story first appeared in our sister publication, Crain's Chicago Business.

Read the rest here:
$30 billion hedge fund's next bet is on biopharmaceuticals - ModernHealthcare.com

The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB) gained about 6% for the week.

Large-cap pharma names AstraZeneca plc (NYSE: AZN) and Novartis AG (NYSE: NVS) received FDA nods for their heart failure and lung cancer therapies, respectively. After receiving emergency use authorization from the FDA in the U.S., Gilead Sciences, Inc.'s (NASDAQ: GILD) remdesivir obtained full regulatory approval in Japan.

Moderna Inc (NASDAQ: MRNA) received the OK toproceedwith the Phase 2 trial of its mRNA coronavirus vaccine candidate mRNA-1273.

The following are the key events and catalysts that biotech investors need to watch in the coming week.

Clovis Oncology Inc (NASDAQ: CLVS) awaits the FDA nod for an expanded indication for its cancer therapy Rubraca. The sNDA seeks approval of Rubraca as a monotherapy treatment for patients with BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer.

Abeona Therapeutics Inc (NASDAQ: ABEO) is due to present updated interim results from the Transpher A and Transpher B studies, Phase 1/2 trials of ABO-102 and ABO-101, respectively, in mucopolysaccharidosis type IIIA, aka as Sanfilippo syndrome type.

Rocket Pharmaceuticals Inc (NASDAQ: RCKT will present updated data from Phase 1/2 FANCOLEN-I study, which is evaluating the safety and efficacy of infusion of autologous CD34 + cells transduced with a lentiviral vector carrying the FANCA gene in patients with Fanconi anemia subtype A, and updates from the Phase 1 LAD-I study that is evaluating its investigational gene therapy RP-L201 to treat severe Leukocyte Adhesion Deficiency-I.

Avrobio Inc (NASDAQ: AVRO) is scheduled to make an oral presentation on new data from the Phase 2 trial of AVR-RD-01 for Fabry (Wednesday). The company will also make an oral presentation of new data from the collaborator-sponsored Phase 1/2 clinical trial of AVR-RD-04 in cystinosis. Another oral presentation on new data from a preclinical research program for a gene therapy for Pompe disease is also scheduled for Wednesday.

Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) is due to present updated data from the first three cohorts of a Phase 1/2 study of DTX301 in treating ornithine transcarbamylase deficiency (Wednesday). The company will also present updated data from the confirmatory cohort from a Phase 1/2 study of DTX401 in glycogen storage disease Type 1a (Friday).

Pfizer Inc. (NYSE: PFE) will present Phase 1b data for PF-06939926 in Duchenne muscular dystrophy on Friday.

Krystal Biotech Inc (NASDAQ: KRYS) will present a poster on KB407, an HSV-1 based gene therapy vector, for the treatment of cystic fibrosis.

See Also: Gilead Works To 'Maximize Global Supply' Of Coronavirus Candidate Remdesivir Amid Threat Of Patent Loss

Genocea Biosciences Inc (NASDAQ: GNCA) will host a KOL symposium with a live Q&A for analysts and investors to reflect on the progress of the T cell therapy landscape and provide an in-depth profile of GEN-011 Genocea's neoantigen cell therapy. (Tuesday)

Krystal Biotech is due to present at the SID meeting withresults froma Phase 1/2 study of in vivo gene therapy KB105 for treating autosomal recessive congenital ichthyosis as well as results of a Phase 1/2 trial that is evaluating in vivo correction of dystrophic epidermolysis bullosa by direct cutaneous COL7A1 gene replacement.

Caladrius Biosciences Inc (NASDAQ: CLBS) will present at the SCAI meeting Thursday with full data from the ESCaPE-CMD study of CLBS16 for the treatment of coronary microvascular dysfunction.

Constellation Pharmaceuticals Inc (NASDAQ: CNST) said abstracts of a presentation due at the June 11-14 European Hematology Association meeting will be made available Thursday. The abstract pertains to an interim update from the MANIFEST Phase 2 study that is evaluating CPI-0610 in myelofibrosis.

Auris Medical Holding Ltd (NASDAQ: EARS) is due to release top-line data in early May from the Phase 1b trial that is evaluating AM-201 in healthy volunteers. AM-201 is the company's investigational drug for the prevention of antipsychotic-induced weight gain and somnolence.

Monday

Tuesday

Wednesday

Thursday

Friday

ORIC Pharmaceuticals Inc (NASDAQ: ORIC)

2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Follow this link:
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight - Benzinga

Back in the pre-pandemic era, I was really looking forward to April 8. On that date,Carl Zimmerwas going to give a talk at my school, Stevens Institute of Technology, about his latest book,She Has Her Mothers Laugh. For decades, Zimmer has reported on biology in The New York Times and other publications and in books,13 so far.Mothers Laughtells the epic tale of our attempts to plumb the mysteries of heredity and to improve ourselves with that knowledge. The book is a marvelous work of historyZimmers account of the early days of eugenics in the U.S. is especially grippingas well as a detailed, up-to-date report on CRISPR and other advances that add urgency to old debates about human enhancement. Zimmer is an engaging story-teller and insatiable reporter, who visits scientists in their labs and even volunteers to be a subject. As a result, while discussing the remarkable diversity of creatures dwelling on and in our bodies, he can tell you that his own bellybutton harbors a bacterium,Marimonas, also found in the Mariana Trench. In lieu of Carls April 8 talk, here he answers questions about genetics and related topics. John Horgan

Horgan:How did you end up in the science-writing racket, anyway? Any regrets?

Zimmer:I feel incredibly lucky to have this job. It wasn't anything I thought about with any foresight. I loved to write, and I loved science. A couple years out of college, I got a job as an assistant copy editor at the science magazineDiscover. There, I got a great training in how to fact-check and report on science. I stayed there for ten years before heading out on my own.

Horgan:Why the focus on biology? When you started out, wasnt physics going to solve everything?

Zimmer:As a junior reporter atDiscover, I had to write about all sorts of stuff--astronomy, geoscience, physics, technology, and so on. But I found that biology was always the field that managed to surprise me the most. Evolution has gone off in such crazy directions in the past four billion years, and the tools biologists have to study life have grown incredibly powerful over the past few decades.

Horgan:I sometimes worry Im too mean to scientists. Do you ever worry youre too nice?

Zimmer:As a fact-checker, you learn that no one should be given a pass. When I report on a story, I talk with outside experts to see if researchers I'm writing about are really delivering on what they claim. And it's also important to keep up with what social scientists and philosophers have to say--because science doesn't happen in a vacuum and can have dangerous consequences.

Horgan:Whats the biggest thing thats happened in science since you started writing about it?

Zimmer:DNA sequencing. It changed everything, from the study of Neanderthals to tracking the covid-19 pandemic.

Horgan:In 2009you quit the online chat show Bloggingheads.tv, on whichwe once spoke, because it gave a platform to creationists. Have your feelings about creationism evolved over the past decade?

Zimmer:No. Creationists have not done any good science since then, while evolutionary biology has leapt forward in dramatic fashion.

Horgan:Whenever I criticize scientificracism, orsexism, people call me an unscientific social justice warrior. I knowthis happens to you, too. How do you deal with these people?

Zimmer:People try to deflect from weak arguments by accusing their opponents of being contemptible.

Horgan:Is CRISPR living up to its hype? If so, will it help gene therapy, finally, take off?

Zimmer:CRISPR is already a mainstay of scientific research, for testing how genes work and how mutations affect health. It's already into clinical trials for diseases like sickle cell anemia just few years after its invention. We have yet to see how well it will work in those applications. But it's unquestionably one of the most important advances in the history of biology.

Horgan:By the time I reached the end ofShe Has Her Mothers Laugh, I wasnt sure whether you think genetic enhancement of humans is feasible, or desirable. Could you clarify?

Zimmer:I think anyone who pretends to have a simple answer is wrong. The answer depends not only on the complexity of biology, but also on what we really want from genetic enhancement. We are already carrying out genetic enhancement when parents with Huntington's disease pick embryos for IVF without the mutation. But I'm skeptical that any manipulation will affect, say, intelligence--certainly not more than what a decent education and a healthy childhood can offer.

Horgan:Will there be any more revolutions in our understanding of heredity?

Zimmer:It's not possible to predict revolutions that haven't happened. But I think that scientists will learn a lot about how epigenetic changes can be carried down through generations--if not in humans, then in other animals and plants.

Horgan:Will our knowledge ever be so complete that the nature/debate finally ends?

Zimmer:I can't rule it out, but it won't be easy. It's relatively easy to study how genes influence variation, but the environment is so vast and complex it may not submit to simple experiments with clear results. Still, there are some very impressive experiments that are grappling with these challenges.

Horgan:Are radical life extension, and possibly immortality, feasible?

Zimmer:I'm not holding my breath. Aging is the result of so many factors that it's hard to see how any simple intervention can change it much. Immortality just seems biologically silly to me.

Horgan:I cant resist asking: what do you think of the U.S. response to the coronavirus?

Zimmer:A disaster.

Further Reading:

Was Darwin Wrong?

How Can We Curb the Spread of Scientific Racism?

Should Research on Race and IQ Be Banned?

My Problem with Taboo Behavioral Genetics? The Science Stinks!

Quest for Intelligence Genes Turns Out More Dubious Results

Have Researchers Really Discovered Any Genes for Behavior?

Defending Stephen Jay Goulds Crusade Against Biological Determinism

Darwin Was Sexist, and So Are Many Modern Scientists

Do Women Want to be Oppressed?

Google Engineer Fired for Sexist Memo Isnt a Hero

See also my free, online bookMind-Body Problems: Science, Subjectivity & Who We Really Are, also available as a Kindle e-book and paperback.

Original post:
Will the Nature/Nurture Debate Ever End? - Scientific American

Global Parkinsons disease treatment Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, Regional and Country Level.

Parkinsons disease treatment Market Size Covers Global Industry Analysis, Size, Share, CAGR, Trends, Forecast And Business Opportunity.

>>Need a PDF of the global market report? Visit: https://industrystatsreport.com/Request/Sample?ResearchPostId=71&RequestType=Sample

Global Parkinsons disease treatment Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2018-2024Scope of Global Parkinsons disease treatment Market Reports

Parkinsons disease is a neuro degenerative disorder in which parts of the brain become progressively damaged over many years. It is a type of movement disorder. It occurs when nerve tissue unable to produce a chemical named Dopamine which is used to send signals that help you move your body. Parkinsons disease usually developed for aged people i.e. above 60 years, but it can also start earlier. It is more common in men than in women. The cause of Parkinsons disease is unknown, but researchers think that both genetic and environmental factors are involved. Primary symptoms include tremors, Stiffness, Slowness, impaired balance, mild memory & Thinking problem and shuffling gait. Secondary symptoms include Anxiety, Depression, Fatigue, Low blood pressure, muscle cramp, Speech & communication problem, skin & Dental Problem and Dizziness, and Dementia. Risk of Parkinsons disease increases with age and the disease mainly affects person over 50 years of age. The development of Parkinsons disease and the degree of destruction differ from person to person. Many people with Parkinsons disease live long productive lives, whereas others become disabled much more quickly. As symptoms worsen, it may become difficult to walk, talk, and complete simple tasks. Malnutrition and weight maintenance is common problem for people with Parkinsons disease. There is no test to diagnose Parkinsons disease with certainty. Treatment options include medication or surgical treatment. Combination of Levodopa with carbidopa is considered as a gold standard for symptomatic treatment of Parkinsons disease. Surgical treatment options include deep brain stimulation and Carbidopa/levodopa enteral suspension therapy but surgical therapy is effective only for patients who have previously responded to Levodopa therapy. Commercially available drugs for treatment of Parkinsons disease are Sinemet, Safinamide, Rotigotine, Ropinirole, Pramiprexol, Amantidine, Cycloset, Parlodel (Bromocriptine Mesylate), Rytary, Azilect, Northera, Stalevo, Comtess/Comtan and others. More than past decade, huge improvement has been made in the treatment of Parkinsons disease such as identification of new therapeutic targets through genetic research, understanding the common mutations that contribute to Parkinsons disease etc.

Global Parkinsons diseases Treatment Market report is segmented on the basis of Medication, Medical devices, End user, Distribution Channels and Geography. Based on Medication Global Parkinsons disease Treatment Market is classified into Dopamine Precursors, Peripheral Decarboxylase Inhibitors, COMT (Catechol-O-methyltransferase) Inhibitors, MAO (Monoamine Oxidase), Inhibitors and Others (anticholinergics, antihistaminics etc.)

On the basis of Medical Devices Global Parkinsons disease Treatment Market is classified into Deep Brain Stimulation (DBS) Devices, Carbidopa/Levodopa Enteral Suspension (Duopa) delivery devices and others. On the basis of End User Global Parkinsons disease Treatment Market is classified into Hospitals, Homecare setting, Clinics and Others. On the basis of Distribution Channel Global Parkinsons disease Drug Market is classified into Retail Pharmacies, Online Pharmacies, Hospital Pharmacies and Drug Stores.

The regions covered in Global Parkinsons diseases Treatment Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, Global Melanoma Drug Market sub divided in to U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Key Players for Global Parkinsons disease treatment Market Reports

Global Parkinsons disease Treatment Market reports cover prominent players like Teva Pharmaceuticals, AstraZeneca, Novartis AG, Boehringer Ingelheim, GlaxoSmithKline Plc., Salix Pharmaceuticals, mpax Laboratories, Orion Corporation, Mylan N.V., Cipla Inc., Daiichi Sankyo, Apotex Inc, Impax Laboratories, Lundbeck, Sun Pharma, Wockhardt ,UCB, Valeant Pharmaceuticals Acadia, Abbvie, Zydus Cadilla, Strides, 1 A Pharma, Upsher-Smith, Intas, US World Meds, Dr. Reddys, Medtronic plc, Biotie Therapies Corp., Adamas Pharmaceuticals Inc., Akorn Inc., Astellas Pharma Inc., Desitin Arzneimittel GmbH, Endo International plc, Kyowa Hakko Kirin, Newron Pharmaceuticals and Merck.

Global Parkinsons disease treatment Market Dynamics

Global Parkinsons disease Treatment Market is mainly driven by growing prevalence of Parkinsons disease and government funding for research on Parkinsons disease. The increase in number of geriatric population and technological advancements such as combination therapies for prolong action of continuous dopaminergic stimulation drugs, gene therapy, neural transplantation are few other causes which are possible to boost the Parkinsons disease Treatment market. However some restraints like availability of alternative treatments is expected to hold back market and expiry of patents for several drugs such as Stalevo, Azilect, Rytary, Comtan etc. can cause the termination of Parkinsons disease Treatment market. High cost of treatment such as 14.4 Billion USD and lack of expertise for early diagnosis is likely to restrict the market growth.

Also lack of novel and successful therapies in the market to reduce the risk of mortality restraints for this market. The opportunities for Global Parkinsons disease Treatment market includes upcoming technologies like surface EMG (Electromyography) sensors, Pulse oximetry sensors, development in personalized medicine along with huge investment in anti-Parkinsons drugs research will boost the global Parkinsons disease Treatment market. Also development of novel drugs and combination therapy with less side effects and better survival rates is expected to increase the global Parkinsons disease Treatment market.

Global Parkinsons disease treatment Market Regional Analysis

Europe is likely to achieve the largest share of the global Parkinsons disease treatment market, which is expected to be followed by North America with a sizeable market share. High knowledge about the treatment, increase in expenditure for Research & Development, favorable medicinal reimbursement regulations and policies, the high occurrence of Parkinsons disease, the rapidly growing geriatric population and potential medical pipeline products are likely to contribute to the major share of Europe in Global Parkinsons disease treatment market. The global Parkinsons disease treatment market in the Asia Pacific is anticipated to develop at a profitable rate. The market share of the global Parkinsons disease treatment market is to be expected to grasp by China and Japan in the Asia Pacific, due to the large population of elderly people who are affected with Parkinsons disease.

Furthermore, increase in awareness of disease and government initiatives for improving health care facilities are expected to boost the regional market to a certain extent.

Key Benefits for Global Parkinsons disease treatment Market Reports

Global Parkinsons disease Treatment Market report covers in depth historical and forecast analysis.Global Parkinsons disease Treatment Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Global market sale (K Units), Global market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.Global Parkinsons disease Treatment Market report helps to identify opportunities in market place.Global Parkinsons disease Treatment Market report covers extensive analysis of emerging trends and competitive landscape.Global Parkinsons disease treatment Market Segmentation

Global Parkinsons disease Treatment Market: By Medication Analysis

Dopamine PrecursorPeripheral Decarboxylase InhibitorsCOMT (Catechol-O-methyltransferase) InhibitorsMAO(monoamine oxidase) InhibitorsOthers (anticholinergics, antihistaminics etc.)Global Parkinsons disease Treatment Market: By Medical Devices Analysis

Deep Brain Stimulation (DBS) DevicesCarbidopa/Levodopa Enteral Suspension (Duopa) delivery devicesOthersGlobal Parkinsons disease Treatment Market: By End User Analysis

HospitalsClinicsHomecare settingOthersGlobal Parkinsons disease Treatment Market: By Distribution Channel

Retail PharmaciesOnline PharmaciesHospital PharmaciesDrug StoreGlobal Parkinsons disease Treatment Market: By Regional & Country Analysis

North AmericaU.S.MexicoCanadaEuropeUKFranceGermanyItalyAsia PacificChinaJapanIndiaSoutheast AsiaLatin AmericaBrazilThe Middle East and AfricaGCCAfricaRest of Middle East and AfricaNeed a PDF of the global market report? Visit: https://industrystatsreport.com/Request/Sample?ResearchPostId=71&RequestType=Methodology

Table of Content:

Market Overview: The report begins with this section where product overview and highlights of product and application segments of the Global Parkinsons disease treatment Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company: Here, the competition in the Worldwide Global Parkinsons disease treatment Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data: As the name suggests, this section gives the sales data of key players of the Global Parkinsons disease treatment Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the Global Parkinsons disease treatment Market.

Market Status and Outlook by Region: In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the Global Parkinsons disease treatment Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User: This section of the research study shows how different end-user/application segments contribute to the Global Parkinsons disease treatment Market.

Market Forecast: Here, the report offers a complete forecast of the Global Parkinsons disease treatment Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion: This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Follow this link:
Covid 19 Pandemic: Parkinsons disease treatment Market Size, Share & Trends Analysis Report By Product, By Technology, By Application, By End Use,...